Introduction About GLIBEKIND M 5/850 TABLET

Type II diabetes mellitus is a chronic disease characterized by abnormally high levels of glucose in the blood. It is caused due to inadequate production of a hormone called insulin (produced by pancreas to metabolize glucose) in the body or if the body cannot utilize the secreted insulin properly.

Glibenclamide is a sulfonylurea. It reduces blood glucose levels by making the pancreas secrete more insulin. Metformin is a biguanide. It blocks the amount of glucose produced by the liver. It also reduces the absorption of glucose in the intestines and allows the body to utilize the circulating insulin.

Before taking GLIBEKIND M 5/850 TABLET, inform your doctor if you have any heart, liver, or kidney problems. You must also inform your doctor if you have any hormonal problems or if you are severely dehydrated, malnourished, starved, on an irregular diet.

GLIBEKIND M 5/850 TABLET is not suitable for use in patients with type I diabetes mellitus. Consult your doctor before taking GLIBEKIND M 5/850 TABLET if you are pregnant or planning to become pregnant or are breastfeeding.

One of the most common side effects of taking GLIBEKIND M 5/850 TABLET is hypoglycemia (low blood sugar levels) which can be identified by symptoms such as increased hunger, sweating, shakiness, weakness, or an irregular heartbeat. To avoid this, your doctor will periodically monitor your blood sugar levels and adjust the dose of GLIBEKIND M 5/850 TABLET accordingly.

You can also carry a sugary snack (such as biscuits, glucose drinks or sweet candies) along with you as a precaution and have them immediately if you experience any signs of hypoglycemia. However, consult your doctor if there is no improvement in your condition. Other common side effects of taking GLIBEKIND M 5/850 TABLET are headache, dizziness, nausea, weight gain and changes in taste. Contact your doctor if any of these side effect worsens.

• Manage type II diabetes mellitus

Your doctor will decide the correct dose and duration of therapy for you depending upon your age, body weight and disease condition. Continue to take GLIBEKIND M 5/850 TABLET for the stipulated duration instructed by your doctor without any interruption to achieve better results.

A. Drug-Drug interactions:

Before taking GLIBEKIND M 5/850 TABLET, inform your doctor if you are taking any of the following medicines such as:

• Other medicines to manage diabetes mellitus (such as insulin, glimepiride, pioglitazone)
• Medicines used to manage high blood pressure (Ex. captopril, enalapril, lisinopril, losartan, valsartan, olmesartan, clonidine, guanethidine and reserpine)
• Medicines to control blood high cholesterol level (Ex. fenofibrate, colesevalam and nicotinic acid)
• Medicines used to manage edema such as diuretics (Ex. furosemide, chlorothiazide)
• Medicines used to manage pain and inflammation (such as ibuprofen, celecoxib, phenylbutazone, azopropazone, oxyphenbutazone)
• Medicines used to manage asthma (Ex. salbutamol or terbutaline)
• Bosentan (a medicine used to manage high blood pressure)
• Corticosteroids (used to manage inflammation) Ex. prednisolone
• Verapamil (a medicine used to manage heart problems)
• Rifampicin (an antibiotic used to manage tuberculosis)
• Cimetidine (a medicine used to manage stomach problems)
• Medicines used to manage bacterial infections (Ex. tetracyclines, chloramphenicol, clarithromycin)
• Medicines used to manage fungal infections (Ex. fluconazole, miconazole)
• Medicines used for blood thinning (Ex. warfarin)
• Medicines used to manage depression (Ex. fluoxetine, escitalopram, sertraline)
• Medicines used to manage severe mental disorders (Ex. chlorpromazine)
• Medicines used to manage gout (Ex. probenecid, sulfinpyrazone)
• Medicines used to manage cancer (Ex. cyclophosphamide, ifosfamide)
• Medicines used to manage thyroid deficiency (Ex. thyroxine)
• Sympathomimetics (used to improve heartbeat and to manage asthma or nasal congestion) Ex. adrenaline, ephedrine

Overdosage:

If you or anyone else accidentally take too much of GLIBEKIND M 5/850 TABLET, consult your doctor immediately or go to a hospital straight away. Symptoms of overdose might include rapid breathing, severe drowsiness, slow/irregular heartbeat, passing out or trouble breathing.

A: Yes. GLIBEKIND M 5/850 TABLET may cause weight gain in some individuals. To avoid this, follow a healthy diet and regular physical activity as advised by your physician. However, if it bothers you, consult your doctor.

Q: How to take GLIBEKIND M 5/850 TABLET?

A: You must take GLIBEKIND M 5/850 TABLET as advised by your physician. Try to take GLIBEKIND M 5/850 TABLET preferably after meals. Swallow the medicine with a glass of water. Do not crush or chew the medicine.

Q: Can GLIBEKIND M 5/850 TABLET be taken with insulin?

A: Consult your doctor before taking GLIBEKIND M 5/850 TABLET along with insulin, as it may increase the chances of hypoglycemia (decreased blood sugar levels).

Q: How much GLIBEKIND M 5/850 TABLET should I take?

A: GLIBEKIND M 5/850 TABLET should be used only under medical supervision. Your doctor will decide the correct dose and duration of therapy for you depending upon your age, body condition and severity of the disease condition.

Q: What should I do if I experience low blood sugar after taking GLIBEKIND M 5/850 TABLET?

A: Low blood sugar is a common side effect of taking GLIBEKIND M 5/850 TABLET. Try to have sugar rich food items such as fruit juice, glucose tablets or gel, soft drinks, honey, or sugary candy. If you cannot any improvement in your condition or if your condition worsen, contact your doctor.

Q: Can GLIBEKIND M 5/850 TABLET cause dizziness?

A: Yes. Dizziness is a common side effect of using GLIBEKIND M 5/850 TABLET. In case you experience dizziness, lie down until it passes, then get up slowly and carefully. Get adequate rest. Drink plenty of water and other fluids. Avoid smoking and consumption of alcohol. Do not drive or use machinery to avoid accidents. Consult your doctor if you experience dizziness continuously for a long time after taking GLIBEKIND M 5/850 TABLET.

Q: What are the side effects of GLIBEKIND M 5/850 TABLET?

A: One of the most common side effects of taking GLIBEKIND M 5/850 TABLET is hypoglycemia (low blood sugar levels). To manage this, you can snack on foods rich in sugars such as biscuits, candies etc. Other common side effects of taking GLIBEKIND M 5/850 TABLET are headache, dizziness, nausea, weight gain and changes in taste. Contact your doctor if any of these side effect worsens.

Q: What precautions do I need to follow while taking GLIBEKIND M 5/850 TABLET?

A: Before taking GLIBEKIND M 5/850 TABLET, inform your doctor if you have any liver, kidney or heart problems. You must also inform your doctor if you have hormonal problems or if you are malnourished. GLIBEKIND M 5/850 TABLET is not suitable for use in patients with type I diabetes mellitus. Consult your doctor before taking GLIBEKIND M 5/850 TABLET if you are pregnant or planning to become pregnant. During therapy with GLIBEKIND M 5/850 TABLET, follow the diet and lifestyle changes instructed by your doctor. Always carry a sugary snack (such as biscuits, glucose drinks or sweet candies) along with you as a precaution and have them immediately if you experience any signs of hypoglycemia.

Q: What GLIBEKIND M 5/850 TABLET does to your body?

A: GLIBEKIND M 5/850 TABLET effectively controls blood sugar levels in patients with type II diabetes mellitus. It reduces blood glucose levels by increasing the amount of insulin secreted by the pancreas and by blocking the amount of glucose produced by the liver. It also reduces the absorption of glucose in the intestines and allows the body to make better use of insulin.

Q: What is the use of GLIBEKIND M 5/850 TABLET?

A: GLIBEKIND M 5/850 TABLET is used in adults to manage type II diabetes mellitus along with diet and exercise.

2. Alan J Garber, Daniel S Donovan Jr, Paresh Dandona, Simon Bruce, Jong-Soon Park. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. NIH: National Library of Medicine, National center of biotechnology Information Pubmed.gov. August 2003. [Accessed on 17th January 2024]. https://pubmed.ncbi.nlm.nih.gov/12915642/

3. Virendra Rambiritch, Breminand Maharaj, and Poobalan Naidoo. Glibenclamide in patients with poorly controlled type 2 diabetes: a 12-week, prospective, single-center, open-label, dose-escalation study. NIH. National Library of Medicine. National Center of Biotechnology Information. PMC. PubMed Central. April 2014. [Accessed on 17th January 2024]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983009/

4. Chanelle Medical. Health Product Regulatory Authority. (HPRA). [Revised in May 2016] [Accessed on 17th January 2024]. https://www.hpra.ie/img/uploaded/swedocuments/2179143.PA0688_040_002.752e1eeb-1045-476a-97ac-9f7549199666.000001Product%20Leaflet%20Approved%205mg.160725.pdf

5. Milpharm Limited. Electronic Medicines Compendium (EMC). [Revised in June 2020] [Accessed on 17th January 2024]. https://www.medicines.org.uk/emc/files/pil.594.pdf

6. Bristol-Myers Squibb Company; U.S. Food & Drug Administration; [Revised in December 2018] [Accessed on 17th January 2024]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021178s018lbl.pdf

7. Central Drugs Standard Control Organization. Glibenclamide+Metformin. [Accessed on 17th January 2024]. https://cdscoonline.gov.in/CDSCO/Drugs